Lallemand Pharma and GM Pharmaceuticals have introduced new oral vaccine Ismigen in Georgia, US, to prevent acute exacerbations in chronic obstructive pulmonary disease.

Ismigen, a polyvalent mechanical bacterial lysate, is also used to prevent acute, sub-acute, recurrent or chronic infections of the upper and lower airways and the bronchopulmonary tree.

The drug is prepared from a large array of inactivated pathogenic bacteria via mechanical lysis.

Switzerland-based Lallemand Pharma’s key products are comprised of immunostimulant drugs Ismigen, Immubron and Respibron, which target infections of the respiratory tract.